TY - JOUR
T1 - ω-3 Polyunsaturated fatty acid biomarkers and coronary heart disease
T2 - Pooling project of 19 cohort studies
AU - Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCe)
AU - Del Gobbo, Liana C.
AU - Imamura, Fumiaki
AU - Aslibekyan, Stella
AU - Marklund, Matti
AU - Virtanen, Jyrki K.
AU - Wennberg, Maria
AU - Yakoob, Mohammad Y.
AU - Chiuve, Stephanie E.
AU - Dela Cruz, Luicito
AU - Frazier-Wood, Alexis C.
AU - Fretts, Amanda M.
AU - Guallar, Eliseo
AU - Matsumoto, Chisa
AU - Prem, Kiesha
AU - Tanaka, Tosh
AU - Wu, Jason H.Y.
AU - Zhou, Xia
AU - Helmer, Catherine
AU - Ingelsson, Erik
AU - Yuan, Jian Min
AU - Barberger-Gateau, Pascale
AU - Campos, Hannia
AU - Chaves, Paulo H.M.
AU - Djoussé, Luc
AU - Giles, Graham G.
AU - Gómez-Aracena, Jose
AU - Hodge, Allison M.
AU - Hu, Frank B.
AU - Jansson, Jan Håkan
AU - Johansson, Ingegerd
AU - Khaw, Kay Tee
AU - Koh, Woon Puay
AU - Lemaitre, Rozenn N.
AU - Lind, Lars
AU - Luben, Robert N.
AU - Rimm, Eric B.
AU - Risérus, Ulf
AU - Samieri, Cecilia
AU - Franks, Paul W.
AU - Siscovick, David S.
AU - Stampfer, Meir
AU - Steffen, Lyn M.
AU - Steffen, Brian T.
AU - Tsai, Michael Y.
AU - Van Dam, Rob M.
AU - Voutilainen, Sari
AU - Willett, Walter C.
AU - Woodward, Mark
AU - Mozaffarian, Dariush
N1 - Publisher Copyright:
© 2016 American Medical Association. All Rights Reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Importance: The role of ω-3 polyunsaturated fatty acids for primary prevention of coronary heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated self-reported consumption rather than biomarkers. Objective: To evaluate biomarkers of seafood-derived eicosapentaenoic acid (EPA; 20:5 ω-3), docosapentaenoic acid (DPA; 22:5 ω-3), and docosahexaenoic acid (DHA; 22:6 ω-3) and plant-derived α-linolenic acid (ALA; 18:3 ω-3) for incident CHD. Data Sources: A global consortium of 19 studies identified by November 2014. Study Selection: Available prospective (cohort, nested case-control) or retrospective studies with circulating or tissue ω-3 biomarkers and ascertained CHD. Data Extraction and Synthesis: Each study conducted standardized, individual-level analysis using harmonized models, exposures, outcomes, and covariates. Findings were centrally pooled using random-effects meta-analysis. Heterogeneity was examined by age, sex, race, diabetes, statins, aspirin, ω-6 levels, and FADS desaturase genes. Main Outcomes and Measures: Incident total CHD, fatal CHD, and nonfatal myocardial infarction (MI). Results: The 19 studies comprised 16 countries, 45 637 unique individuals, and 7973 total CHD, 2781 fatal CHD, and 7157 nonfatal MI events, with ω-3 measures in total plasma, phospholipids, cholesterol esters, and adipose tissue. Median age at baselinewas 59 years (range, 18-97 years), and 28 660 (62.8%)were male. In continuous (per 1-SD increase) multivariable-adjusted analyses, the ω-3 biomarkers ALA, DPA, and DHAwere associated with a lower risk of fatal CHD, with relative risks (RRs) of 0.91 (95%CI, 0.84-0.98) for ALA, 0.90 (95%CI, 0.85-0.96) for DPA, and 0.90 (95%CI, 0.84-0.96) for DHA. Although DPA was associated with a lower risk of total CHD (RR, 0.94; 95%CI, 0.90-0.99), ALA (RR, 1.00; 95%CI, 0.95-1.05), EPA (RR, 0.94; 95%CI, 0.87-1.02), and DHA (RR, 0.95; 95%CI, 0.91-1.00)were not. Significant associations with nonfatal MIwere not evident. Associations appeared generally stronger in phospholipids and total plasma. Restricted cubic splines did not identify evidence of nonlinearity in dose responses. Conclusions and Relevance: On the basis of available studies of free-living populations globally, biomarker concentrations of seafood and plant-derived ω-3 fatty acids are associated with a modestly lower incidence of fatal CHD.
AB - Importance: The role of ω-3 polyunsaturated fatty acids for primary prevention of coronary heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated self-reported consumption rather than biomarkers. Objective: To evaluate biomarkers of seafood-derived eicosapentaenoic acid (EPA; 20:5 ω-3), docosapentaenoic acid (DPA; 22:5 ω-3), and docosahexaenoic acid (DHA; 22:6 ω-3) and plant-derived α-linolenic acid (ALA; 18:3 ω-3) for incident CHD. Data Sources: A global consortium of 19 studies identified by November 2014. Study Selection: Available prospective (cohort, nested case-control) or retrospective studies with circulating or tissue ω-3 biomarkers and ascertained CHD. Data Extraction and Synthesis: Each study conducted standardized, individual-level analysis using harmonized models, exposures, outcomes, and covariates. Findings were centrally pooled using random-effects meta-analysis. Heterogeneity was examined by age, sex, race, diabetes, statins, aspirin, ω-6 levels, and FADS desaturase genes. Main Outcomes and Measures: Incident total CHD, fatal CHD, and nonfatal myocardial infarction (MI). Results: The 19 studies comprised 16 countries, 45 637 unique individuals, and 7973 total CHD, 2781 fatal CHD, and 7157 nonfatal MI events, with ω-3 measures in total plasma, phospholipids, cholesterol esters, and adipose tissue. Median age at baselinewas 59 years (range, 18-97 years), and 28 660 (62.8%)were male. In continuous (per 1-SD increase) multivariable-adjusted analyses, the ω-3 biomarkers ALA, DPA, and DHAwere associated with a lower risk of fatal CHD, with relative risks (RRs) of 0.91 (95%CI, 0.84-0.98) for ALA, 0.90 (95%CI, 0.85-0.96) for DPA, and 0.90 (95%CI, 0.84-0.96) for DHA. Although DPA was associated with a lower risk of total CHD (RR, 0.94; 95%CI, 0.90-0.99), ALA (RR, 1.00; 95%CI, 0.95-1.05), EPA (RR, 0.94; 95%CI, 0.87-1.02), and DHA (RR, 0.95; 95%CI, 0.91-1.00)were not. Significant associations with nonfatal MIwere not evident. Associations appeared generally stronger in phospholipids and total plasma. Restricted cubic splines did not identify evidence of nonlinearity in dose responses. Conclusions and Relevance: On the basis of available studies of free-living populations globally, biomarker concentrations of seafood and plant-derived ω-3 fatty acids are associated with a modestly lower incidence of fatal CHD.
UR - http://www.scopus.com/inward/record.url?scp=84980320220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84980320220&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2016.2925
DO - 10.1001/jamainternmed.2016.2925
M3 - Article
C2 - 27357102
AN - SCOPUS:84980320220
SN - 2168-6106
VL - 176
SP - 1155
EP - 1166
JO - JAMA internal medicine
JF - JAMA internal medicine
IS - 8
ER -